Amphion Portfolio Company WellGen Completes $3M Funding
News Feb 23, 2006
The capital raised from this latest round of financing will provide additional resources for WellGen to begin clinical studies in humans under its Obesity and Inflammation Programmes, aimed at developing and bringing to market a variety of new and promising nutritional products on which the company is working.
Investors in this round of financing include both new and existing WellGen shareholders. Amphion’s $1MM investment, previously announced in August 2005, brings its ownership stake in the firm to 19%.
WellGen’s Obesity Programme is based upon the study of a proprietary gene panel comprised of carefully selected genes that are known to be associated with obesity.
Functional food ingredients coming out of this programme are anticipated to control weight via a gene-controlling mechanism of action that is different from those of other products on the market.
Encouraged by animal studies that were completed in late 2005, WellGen anticipates beginning human clinical studies during 2006.
Richard Morgan, CEO of Amphion, said, "With obesity reaching almost epidemic proportions, there is a vast and growing need for safe and effective bioactives to address this important market."
"We are pleased to see WellGen’s patented screening technologies addressing obesity, inflammation, and other equally serious conditions and we’re excited to increase our investment."
David Evans, chief executive officer of WellGen, said, "We are pleased with the results that we are seeing and that our shareholders have confidence in WellGen’s ability to identify, develop and successfully commercialize consequential ingredients for the wellness market."
Bird and Turtle Chromosomes Help Identify Dinosaur DNANews
Researchers have used bird and turtle DNA to extrapolate the chromosome structure of their common ancestor that lived around 260 million years ago – 20 million years before the dinosaurs first emerged. They were then able to trace the evolution of avian and non-avian dinosaur DNA through to the present day.
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE
Yeast Study Performs Hundreds of Simultaneous CRISPR EditsNews
A new technique which can alter hundreds of different genes at once in baker's yeast could greatly speed up CRISPR-Cas9 editing and offer a way to perform high-throughput functional genomics.READ MORE